GlassScriptPhysician profile
Calvin Vanreken
NPI 1710052394
$4,886.61
in general payments reported to CMS, 2019-2025
15 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 94% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $444 · 2021: $286 · 2022: $433 · 2023: $639 · 2024: $911 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,209.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,222.90 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,145.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $451.99 | 2022-2025 | |
| Allergan, INC. | $396.59 | 2019-2020 | |
| Lilly USA, LLC | $368.36 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $251.84 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.86 | 2022-2023 | Jardiance |
| Novo Nordisk INC | $229.38 | 2019-2025 | Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $191.21 | 2024-2025 | Caplyta |
| Bridgebio Pharma, INC. | $137.84 | 2025 | Attruby |
| Pfizer INC. | $110.29 | 2025 | |
| Lundbeck LLC | $78.36 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $32.25 | 2025 | Trintellix |
| Amgen INC. | $20.34 | 2025 | Repatha, Otezla |
| Corcept Therapeutics | $18.90 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Vanreken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.